Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma

Published:2013-06 Issue:5 Volume:28 Page:370-379
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Vaklavas Christos¹,Meredith Ruby F.²,Shen Sui²,Knox Susan J.³,Micallef Ivana N.⁴,Shah Jatin J.⁵,LoBuglio Albert F.¹,Forero-Torres Andres¹

Affiliation:

1. Department of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.

2. Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.

3. Department of Radiation Oncology, Stanford University, Stanford, California.

4. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

5. Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2012.1387

Reference28 articles.

1. Non-Hodgkin Lymphoma: Diagnosis and Treatment

2. Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop

3. Transformation of Indolent B-Cell Lymphomas

4. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials;Cancers;2021-11-07

2. Trial Watch: Radioimmunotherapy for oncological indications;OncoImmunology;2014-09-02